Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab in giant cell arteritis (randomized, double-blind, placebo-controlled Phase 3 study)
2017-002988-18Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in giant cell arteritis (GCA) comparing Sarilumab + prednisone taper with Placebo + prednisone taper (2 arms). Primary endpoint: Sustained remission rate. Started Sep 2018; status: terminated.
02
Drugs
sarilumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2017-002988-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002988-18.